10-Q · May 5, 2026
Nuvectis Pharma, Inc. has reported a net loss for Q1 2026 of $6.1 million, reflecting an increase from a $5.3 million loss in Q1 2025. Operating expenses rose due to higher research and development costs, while cash…
Earnings analysis · 10-Q
NVCT earnings analysis
Filed August 4, 2026 · Our reading of the company's report
The latest report
Nuvectis remained pre-revenue in 2Q26 and reported a net loss of $7.020 million, compared with a $6.334 million loss a year earlier; diluted EPS was negative $0.30, versus negative $0.26 in the preceding quarter and…
Read full summary
Nuvectis remained pre-revenue in 2Q26 and reported a net loss of $7.020 million, compared with a $6.334 million loss a year earlier; diluted EPS was negative $0.30, versus negative $0.26 in the preceding quarter and negative $0.30 a year ago. Higher R&D investment—particularly NXP900 clinical and manufacturing activity—more than offset lower G&A, widening operating loss to $7.197 million from $6.595 million. Liquidity improved materially after quarter-end through $106.3 million of net equity-offering proceeds, but the company faces escalating development spend, continued external-financing needs, and substantial milestone obligations on newly licensed NXP100 and NXP200.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.3
What stood out
-
Pipeline expanded despite zero revenue
The company remained pre-revenue, reporting no revenue from inception through June 30, 2026. It is advancing three principal clinical programs—NXP100, NXP200 and NXP900—following the June 2026 in-licenses of NXP100 and NXP200.
-
R&D investment increased 30%
R&D expense rose $1.1 million, or 30%, year over year to $4.684 million in 2Q26, led by a $0.8 million increase in NXP900 clinical-trial and manufacturing expense and a $0.3 million increase in employee compensation.
-
G&A spending declined year over year
G&A expense declined $0.469 million, or 16%, year over year to $2.513 million, primarily reflecting a $0.508 million reduction in professional and consulting services tied to public-company costs.
-
July financing materially strengthens liquidity
The July equity offering generated approximately $106.3 million of net proceeds after discounts, commissions and estimated expenses, versus $22.2 million of cash and cash equivalents at June 30, 2026. Management says these resources should fund operations and capex for at least 12 months from issuance.
-
No reported capex; cash use funds R&D
Operating cash use was $11.042 million for the first six months of 2026, and investing cash flow was $0. Free cash flow was therefore approximately negative $11.042 million for the six-month period, with no reported capex.
-
Multiple clinical-stage development catalysts
NXP100 has Chinese marketing approval for treatment-naive PNH, while NXP200 has an ongoing Phase 1b expansion study in China. NXP900's Phase 1b combination study with osimertinib commenced in December 2025.
What to watch
-
Losses and operating cash burn increased
Losses and cash burn worsened: 2Q26 net loss was $7.020 million, up $0.686 million year over year, while six-month operating cash outflow increased to $11.042 million from $7.541 million. The accumulated deficit reached $112.8 million as of June 30, 2026.
-
Future funding needs and dilution remain material
The company has no product revenue and says it will require additional capital as it pursues approvals and potential in-licenses or acquisitions. Its shelf registration permits up to $150.0 million of securities, including up to $60.0 million under its ATM, creating a continuing dilution risk.
-
Large new license-payment commitments
New NXP100/NXP200 license obligations include a $20.0 million upfront payment made in July 2026, up to approximately $1.4 billion of potential milestones, and tiered royalties of 9% to 14% of net sales. These commitments raise future development and commercial cost exposure.
-
China sourcing and policy exposure for new assets
A newly emphasized risk is dependence on China-based Haisco for NXP100/NXP200 technology transfer, know-how and certain materials. Changes in U.S.-China trade or regulatory policy could disrupt these programs; the company noted no tariffs affecting operations as of June 30, 2026.
-
Single-source manufacturing concentration
NXP900 manufacturing is concentrated with one CMO for drug substance and one CMO for drug product. A disruption or cGMP failure could delay clinical development, while R&D expense already increased $1.071 million year over year in 2Q26.
-
Clinical attrition illustrated by NXP800
NXP800 development in ovarian cancer will not be pursued after the Phase 1b update, underscoring clinical execution risk. Its license still carries up to $22.0 million in pre-approval milestones and up to $178.0 million in regulatory and commercial milestones.
Management's outlook
No numerical revenue or EPS guidance was provided in the 10-Q. Management states that June 30 cash plus the July 2026 offering proceeds are expected to fund operating expenses and capital expenditures for at least the next 12 months from financial-statement issuance, while also stating it will require additional capital as programs advance.
Earlier filings 4
10-K · February 11, 2026
Nuvectis (NVCT) is a clinical‑stage oncology company centered on a single program, NXP900, which completed a Phase 1a (dose range 20–300 mg/day; dose‑limiting toxicity not reached) and began a Phase 1b expansion in…
10-Q · May 6, 2025
Nuvectis reported no revenue for Q1 and a wider loss: net loss of $5.332 million (EPS -$0.27) versus $4.171 million (EPS -$0.25) in Q1 2024. R&D and G&A rose to $3.680 million and $1.888 million, respectively, driving…
10-K · March 5, 2024
Nuvectis is a clinical-stage oncology company with no approved products and with no revenue; the 10-K emphasizes advancement of two lead programs (NXP800 and NXP900) through Phase 1 development and multiple regulatory…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.